Tissue Sodium in CKD Patients

Introduction: Sodium hemostasis is altered in patients with chronic kidney disease (CKD) due to long term loading, and sodium (23Na) can be deposited in the skin, muscle and skeleton. We measured 23Na content in these tissues of CKD patients, using 23Na magnetic resonance (MR) imaging. Methods: This is a pilot cross-sectional study of CKD stage 4-5D patients and healthy controls. Subjects underwent a 23Na MR study of their right lower leg using a multinuclear-capable 3.0-T MRI. An axial proton T1-weighted fast-low-angle-shot sequence was acquired to delineate the anatomy; followed by a 23Na MR image obtained with a custom-made 23Na coil and sodium-optimized pulse sequences. Concentration maps were generated using saline solutions at different 23Na concentrations as calibration vials. Four regions of interest (ROIs) were drawn: 1) pre-tibial skin, 2) posterior leg skin, 3) tibia, and 4) soleus muscle. Baseline characteristics and blood samples were also collected. Results: 10 controls, 12 CKD and 23 dialysis (10 peritoneal dialysis (PD) and 13 hemodialysis (HD)) subjects participated in the study. 23Na concentration in all four tissues was significantly higher in dialysis patients compared to controls (p-value23Na of HD, PD and CKD groups. Tissue sodium levels correlated strongly with markers of mineral bone disease and inflammation. Associated factors appear to be tissue specific. Conclusion: Dialysis patients were found to have significantly higher 23Na level in their tissues compared to healthy controls. The effect and clinical utility of tissue 23Na remains to be studied

Canadian Society of Nephrology COVID-19 Rapid Response Team Home Dialysis Recommendations

Purpose of program: This paper will provide guidance on how to best manage patients with end-stage kidney disease who will be or are being treated with home dialysis during the COVID-19 pandemic. Sources of information: Program-specific documents, pre-existing, and related to COVID-19; documents from national and international kidney agencies; national and international webinars, including webinars that we hosted for input and feedback; with additional information from formal and informal review of published academic literature. Methods: Members of the Canadian Society of Nephrology (CSN) Board of Directors solicited a team of clinicians and administrators with expertise in home dialysis. Specific COVID-19-related themes in home dialysis were determined by the Canadian senior renal leaders community of practice, a group compromising medical and administrative leaders of provincial and health authority renal programs. We then developed consensus-based recommendations virtually by the CSN work-group with input from ethicists with nephrology training. The recommendations were further reviewed by community nephrologists and over a CSN-sponsored webinar, attended by 225 kidney health care professionals, for further peer input. The final consensus recommendations also incorporated review by the editors at the Canadian Journal of Kidney Health and Disease (CJKHD). Key findings: We identified 7 broad areas of home dialysis practice management that may be affected by the COVID-19 pandemic: (1) peritoneal dialysis catheter placement, (2) home dialysis training, (3) home dialysis management, (4) personal protective equipment, (5) product delivery, (6) minimizing direct health care provider and patient contact, and (7) assisted peritoneal dialysis in the community. We make specific suggestions and recommendations for each of these areas. Limitations: This suggestions and recommendations in this paper are expert opinion, and subject to the biases associated with this level of evidence. To expedite the publication of this work, a parallel review process was created that may not be as robust as standard arms’ length peer-review processes. Implications: These recommendations are intended to provide the best care possible during a time of altered priorities and reduced resources

Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

BACKGROUND: The risk of ventricular arrhythmia with citalopram and escitalopram is controversial. In this study we investigated the association between these two drugs and the risk of ventricular arrhythmia. METHODS: We conducted a population-based retrospective cohort study of older adults (mean age 76 years) from 2002 to 2012 in Ontario, Canada, newly prescribed citalopram (n = 137 701) or escitalopram (n = 38 436), compared to those prescribed referent antidepressants sertraline or paroxetine (n = 96 620). After inverse probability of treatment weighting using a propensity score, the baseline characteristics of the comparison groups were similar. The primary outcome was a hospital encounter with ventricular arrhythmia within 90 days of a new prescription, assessed using hospital diagnostic codes. The secondary outcome was all-cause mortality within 90 days. RESULTS: Citalopram was associated with a higher risk of a hospital encounter with ventricular arrhythmia compared with referent antidepressants (0.06% vs. 0.04%, relative risk [RR] 1.53, 95% confidence intervals [CI]1.03 to 2.29), and a higher risk of mortality (3.49% vs. 3.12%, RR 1.12, 95% CI 1.06 to 1.18). Escitalopram was not associated with a higher risk of ventricular arrhythmia compared with the referent antidepressants (0.03% vs. 0.04%, RR 0.84, 95% CI 0.42 to 1.68), but was associated with a higher risk of mortality (2.86% vs. 2.63%, RR 1.09, 95% CI 1.01 to 1.18). CONCLUSION: Among older adults, initiation of citalopram compared to two referent antidepressants was associated with a small but statistically significant increase in the 90-day risk of a hospital encounter for ventricular arrhythmia

Relative risks for primary and secondary outcomes of patients prescribed escitalopram compared to the referent antidepressants (paroxetine or sertraline).

<p>Relative risks for primary and secondary outcomes of patients prescribed escitalopram compared to the referent antidepressants (paroxetine or sertraline).</p

Baseline characteristics for the escitalopram cohort (pre and post weighting).

<p>Baseline characteristics for the escitalopram cohort (pre and post weighting).</p

Subgroup analyses of the association between citalopram prescription and the risk of a hospital encounter with ventricular arrhythmia or all-cause mortality.

<p><b>Abbreviations:</b> Coronary artery disease (CAD), Congestive heart failure (CHF), Confidence interval (CI).</p

Baseline characteristics for the citalopram cohort (pre and post weighting).

<p>Baseline characteristics for the citalopram cohort (pre and post weighting).</p

Canadian Association of Paediatric Nephrologists COVID-19 Rapid Response: Home and In-Center Dialysis Guidance

Purpose of the program: This article provides guidance on optimizing the management of pediatric patients with end-stage kidney disease (ESKD) who will be or are being treated with any form of home or in-center dialysis during the COVID-19 pandemic. The goals are to provide the best possible care for pediatric patients with ESKD during the pandemic and ensure the health care team’s safety. Sources of information: The core of these rapid guidelines is derived from the Canadian Society of Nephrology (CSN) consensus recommendations for adult patients recently published in the Canadian Journal of Kidney Health and Disease (CJKHD). We also consulted specific documents from other national and international agencies focused on pediatric kidney health. Additional information was obtained by formal review of the published academic literature relevant to pediatric home or in-center hemodialysis. Methods: The Leadership of the Canadian Association of Paediatric Nephrologists (CAPN), which is affiliated with the CSN, solicited a team of clinicians and researchers with expertise in pediatric home and in-center dialysis. The goal was to adapt the guidelines recently adopted for Canadian adult dialysis patients for pediatric-specific settings. These included specific COVID-19-related themes that apply to dialysis in a Canadian environment, as determined by a group of senior renal leaders. Expert clinicians and nurses with deep expertise in pediatric home and in-center dialysis reviewed the revised pediatric guidelines. Key findings: We identified 7 broad areas of home dialysis practice management that may be affected by the COVID-19 pandemic: (1) peritoneal dialysis catheter placement, (2) home dialysis training, (3) home dialysis management, (4) personal protective equipment, (5) product delivery, (6) minimizing direct health care providers and patient contact, and (7) caregivers support in the community. In addition, we identified 8 broad areas of in-center dialysis practice management that may be affected by the COVID-19 pandemic: (1) identification of patients with COVID-19, (2) hemodialysis of patients with confirmed COVID-19, (3) hemodialysis of patients not yet known to have COVID-19, (4) management of visitors to the dialysis unit, (5) handling COVID-19 testing of patients and staff, (6) safe practices during resuscitation procedures in a pandemic, (7) routine hemodialysis care, and (8) hemodialysis care under fixed dialysis resources. We make specific suggestions and recommendations for each of these areas. Limitations: At the time when we started this work, we knew that evidence on the topic of pediatric dialysis and COVID-19 would be severely limited, and our resources were also limited. We did not, therefore, do formal systematic review or meta-analysis. We did not evaluate our specific suggestions in the clinical environment. Thus, this article’s advice and recommendations are primarily expert opinions and subject to the biases associated with this level of evidence. To expedite the publication of this work, we created a parallel review process that may not be as robust as standard arms’ length peer-review processes. Implications: We intend these recommendations to help provide the best care possible for pediatric patients prescribed in-center or home dialysis during the COVID-19 pandemic, a time of altered priorities and reduced resources